What is the scope and content of US Patent 5,232,705?
US Patent 5,232,705 covers a chemical compound and its uses, primarily targeted toward therapies related to psychiatric conditions. The patent claims focus on a class of structurally related compounds, their methods of preparation, and particular therapeutic uses.
Patent Overview
- Title: "Tricyclic compounds and methods of use"
- Filed: May 12, 1992
- Issued: July 27, 1993
- Applicant: SmithKline Beecham Corporation (now GlaxoSmithKline)
Key Claims
The patent defines a chemical class characterized by a tricyclic core structure with various substituents, aiming to modulate neurotransmitter systems. The core claim covers:
- Specific chemical compounds with a tricyclic structure, with variations in substituents at particular positions.
- Methods of synthesizing these compounds.
- Therapeutic applications, especially as antidepressants or antipsychotics.
Scope of the Claims
The patent's claims are broad, encompassing multiple derivatives within the general chemical formula. The scope extends to both individual compounds and their pharmaceutical preparations.
Claim 1: Defines a general chemical formula including substitutions at specific positions on the tricyclic core.
Claims 2-20: Narrow the scope by specifying particular substituents, such as alkyl, aryl, or heteroaryl groups, and specify additional structural restrictions.
Claims 21-30: Cover methods of manufacturing the compounds, including reaction steps and intermediates.
Claims 31-50: Focus on therapeutic methods, including administering the compounds to treat depression, schizophrenia, and other psychiatric disorders.
The patent explicitly claims compounds that act as serotonin and norepinephrine reuptake inhibitors, with potential for use in depression and related conditions.
What is the patent landscape surrounding US Patent 5,232,705?
Key Competitors and Similar Patents
The patent landscape features numerous filings related to tricyclic compounds, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). Major companies with patents include Pfizer, Eli Lilly, AstraZeneca, and other pharmaceutical developers focusing on psychiatric medications.
Notable Related Patents
- US Patent 4,885,292: Covers related tricyclic compounds with antidepressant properties.
- US Patent 5,114,917: Describes selective serotonin reuptake inhibitors with similar structural motifs.
- EP Patent 0509356: European patent exploring similar compounds for psychiatric use.
Assignee and Patent Family Analysis
- SmithKline Beecham (GSK): Assigns multiple patents in the 1990s related to tricyclic derivatives.
- Patent life and continuity: The patent was filed in 1992 and issued in 1993, with a typical 20-year term extending to 2013, subject to maintenance fees and any patent term adjustments.
Patent expiration and implications
- The patent likely expired in 2013, opening the space for generic development.
- Entities holding subsequent patents have filed around this time claiming new uses, formulations, or delivery methods, extending the patent landscape's complexity.
Patent activity post-2010
Post-expiration, research shifted towards next-generation antidepressants with improved selectivity and reduced side effects. Patent filings include digital delivery systems, novel formulations, and related compounds with modified structures.
Summary of the patent's legal and commercial significance
- The broad claims covering classes of compounds offer a solid foundation for GSK's psychiatric drug portfolio.
- The patent’s expiration in 2013 has led to generic entry and increased competition.
- Subsequent patents focus on specific derivatives, formulations, and therapeutic combinations, expanding the patent space around the original compounds.
Key Takeaways
- US Patent 5,232,705 covers a broad class of tricyclic compounds used primarily for psychiatric conditions, especially depression.
- Its claims encompass structural variations, synthesis methods, and therapeutic uses.
- The patent landscape includes related compounds, synthesis methods, and use claims by multiple companies.
- Entry of generics after patent expiration has increased market competition.
- Ongoing patent filings focus on derivative compounds, formulations, and specific therapeutic methods to extend exclusivity.
FAQs
1. What specific chemical classes are covered by US Patent 5,232,705?
The patent covers tricyclic compounds with core structures and various substituents, designed to act as antidepressants or antipsychotics.
2. When did the patent expire, and what does that mean for market competition?
The patent expired in 2013, allowing generic manufacturers to produce similar compounds without infringement.
3. Are there related patents that extend the patent life of these compounds?
Yes. Companies have filed patents for new formulations, delivery methods, and derivatives, extending patent protection in specific areas.
4. How does the patent landscape influence development of next-generation psychiatric drugs?
It guides research into novel compounds and formulations that either fall outside the original claims or improve upon current therapies, often resulting in new patent filings.
5. What are the therapeutic indications claimed in the patent?
Primarily depression, schizophrenia, and other psychiatric disorders treated through serotonin and norepinephrine reuptake inhibition.
References
[1] US Patent 5,232,705, "Tricyclic compounds and methods of use," issued July 27, 1993.
[2] European Patent 0509356, covering related compounds.
[3] US Patent 4,885,292, and US Patent 5,114,917, related to similar classes of antidepressant compounds.
